Search

Search Constraints

You searched for: Author/Creator Bickel, Markus

Search Results

1. Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial. (1st June 2021)

2. Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial. (1st June 2021)

3. Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany. Issue 4 (4th September 2022)

4. Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients. (September 2014)

5. Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study. (13th August 2020)

6. Evidenz‐ und konsensbasierte (S3) Leitlinie: Impfprävention HPV‐assoziierter Neoplasien. (11th March 2021)

7. German evidence and consensus‐based (S3) guideline: Vaccination recommendations for the prevention of HPV‐associated lesions. (26th February 2021)

8. Identification of a new epitope for HIV‐neutralizing antibodies in the gp41 membrane proximal external region by an Env‐tailored phage display library. Issue 2 (27th December 2012)

9. Immune Response after a Single Dose of the 2010/11 Trivalent, Seasonal Influenza Vaccine in HIV-1–Infected Patients and Healthy Controls. Issue 4 (July 2013)

10. LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. (26th November 2018)